and development costs and longer than average cycle time in both clinical trial execution and regulatory agency review. Some companies have paused or de-prioritised their drug discovery and clinical trial efforts in psychiatry3. However, there are many (183) clinical trials underway or registered, showing there is still considerable investment in the field. (Supp Table 1 provides details of current and recent trials in psychiatry, including the nine PGC3 disorders).
